Chrysea and KaloCyte form exclusive alliance to advance biosynthetic blood solutions

Chrysea and KaloCyte have entered into an exclusive strategic alliance intended to accelerate development and deployment of a biosynthetic red blood cell substitute for medical emergencies. According to the companies, Chrysea will apply its synthetic biology platform in conjunction with KaloCyte’s a…